Caprock Group LLC Purchases 5,764 Shares of Illumina, Inc. $ILMN

Caprock Group LLC grew its position in Illumina, Inc. (NASDAQ:ILMN) by 39.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,558 shares of the life sciences company’s stock after acquiring an additional 5,764 shares during the quarter. Caprock Group LLC’s holdings in Illumina were worth $2,696,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Capital World Investors boosted its holdings in shares of Illumina by 20.0% in the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares during the period. State Street Corp boosted its holdings in shares of Illumina by 6.8% in the 3rd quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock worth $569,800,000 after purchasing an additional 382,520 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Illumina by 3.1% in the 3rd quarter. AQR Capital Management LLC now owns 3,398,027 shares of the life sciences company’s stock worth $315,915,000 after purchasing an additional 102,147 shares during the period. Bank of America Corp DE boosted its holdings in shares of Illumina by 1.9% in the 2nd quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock worth $184,222,000 after purchasing an additional 35,167 shares during the period. Finally, ARK Investment Management LLC boosted its holdings in shares of Illumina by 25.7% in the 3rd quarter. ARK Investment Management LLC now owns 1,467,879 shares of the life sciences company’s stock worth $139,405,000 after purchasing an additional 299,801 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the sale, the senior vice president directly owned 16,321 shares in the company, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of recent research reports. JPMorgan Chase & Co. dropped their target price on Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a report on Friday, February 6th. TD Cowen reiterated a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Robert W. Baird set a $137.00 target price on Illumina in a report on Friday, February 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. Finally, Stifel Nicolaus lifted their target price on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Six investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Illumina currently has an average rating of “Hold” and an average target price of $129.69.

Illumina Stock Up 1.9%

NASDAQ:ILMN opened at $127.88 on Friday. Illumina, Inc. has a twelve month low of $73.86 and a twelve month high of $155.53. The company has a market cap of $19.43 billion, a price-to-earnings ratio of 23.46, a price-to-earnings-growth ratio of 2.41 and a beta of 1.49. The stock has a fifty day simple moving average of $125.10 and a 200-day simple moving average of $125.62. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same period last year, the company earned $0.95 earnings per share. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Analysts anticipate that Illumina, Inc. will post 5.12 EPS for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.